Antique attended Piramal Pharma’s analyst meet, where the company highlighted its ambitious growth plans, aiming to achieve $2 billion in revenue by CY30. Piramal Pharma’s Contract Development and Manufacturing Organization (CDMO) segment, driven by its ADC platform, is expected to be the key catalyst for growth. The company also projects its complex hospitals portfolio and India consumer health to grow at 12% and 9% CAGR, respectively.
Piramal Pharma’s focus on productivity enhancements and cost optimization is likely to boost EBITDA margins from the current ~15% to ~25%. Additionally, the company is doubling down on its CDMO segment and aims to reduce its net debt/EBITDA ratio from ~3x to under 1x by FY24.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
